Icon

Tasly Pharmaceuticals selects ICON for phase III T89 trial

Monday, November 21, 2011 04:52 PM

ICON has been selected by Tasly Pharmaceuticals for the company’s global phase III T89 trial. T89, also known as Dantonic pill, aims to become the first traditional Chinese medicine to receive FDA approval in the United States. Dantonic pill is a botanical product for the treatment of chronic stable angina pectoris due to coronary heart disease. It is a modernized version of a traditional Chinese herbal medicine and was approved by the State Food and Drug Administration (SFDA) of China in 1993. Since then, more than 2 billion doses have been used by over 10 million patients. 

More... »

Survey: ICON Medical Imaging rated top provider

Thursday, November 17, 2011 01:14 PM

Dublin-based ICON has reported that its Medical Imaging division was rated as the top provider of imaging services according to an industry survey conducted by Blue Pyramid Consulting, an affiliate of the Avoca Group.

More... »

ICON's DOCS expands with four new offices in Europe

Wednesday, November 16, 2011 10:11 AM

ICON's resourcing division, DOCS, has expanded in Europe by opening four new offices: in Milan, Italy; Budapest, Hungary; Brussels, Belgium and Berlin, Germany. This latest expansion brings the total number of DOCS offices in Europe to 22.

More... »

ICON, Empire Genomics partner to develop personalized medicines

Wednesday, November 9, 2011 08:02 AM

ICON, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, and Empire Genomics, a provider of genomic technologies that enable personalized medicine to be realized, have formed a strategic alliance.

More... »

ICON named clinical research team of the year

Monday, November 7, 2011 10:10 AM

ICON has won the clinical research team of the year award at the annual 2011 Scrip Awards.

More... »

Survey: 80% of big pharma companies restructuring to strategically outsource more trials to CROs

Monday, October 31, 2011 08:00 AM

According to a recent survey from William Blair, about 80% of big pharma companies either are in the process of restructuring or have already completed restructuring plans to strategically outsource more of their trials to CROs.

More... »

Survey: Top CROs doubled workforce over past decade

Monday, October 24, 2011 08:02 AM

Over the last 10 years, the top nine global CROs have more than doubled their workforce, which now exceeds 72,000 employees, and their revenues have increased at a compound annualized rate of 11% as they increasingly play a larger and more integral role in the drug development infrastructure, according to a new Association of Clinical Research Organizations (ACRO) member survey.

More... »

ICON receives contract award from FNIH

Friday, October 21, 2011 01:38 PM

ICON has received a contract award from the Foundation for the National Institutes of Health (FNIH) to provide clinical support for the Biomarkers Consortium study entitled Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Healthy Subjects. 

More... »

vRad partners with ICON Medial imaging

Monday, October 17, 2011 12:25 PM

Virtual Radiologic (vRad), a technology-enabled national radiology practice, has reported a radiology partnership with ICON Medical Imaging, the medical imaging division of ICON.

More... »

ICON names president of DOCS

Monday, October 17, 2011 10:59 AM

ICON has named Colin Stanley president of DOCS, the company’s global resourcing division. Stanley succeeds Mr. Bill Taaffe as president following his retirement earlier this year.

More... »